Korean J Urol.
2015 Oct;56(10):671-672. 10.4111/kju.2015.56.10.671.
Future directions in overactive bladder treatment: Personalized medicine can be applied?
- Affiliations
-
- 1Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. ksleedr@skku.edu
- 2Department of Medical Device Management and Research, SAIHST, Sungkyunkwan University, Seoul, Korea.
- KMID: 2344108
- DOI: http://doi.org/10.4111/kju.2015.56.10.671
Abstract
- No abstract available.
MeSH Terms
Reference
-
1. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012; 188:6 Suppl. 2455–2463.2. D'Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008; 14:291–301.3. President's Council of Advisors on Science and Technology. Priorities for personalized medicine [Internet]. Washington, DC: Executive Office of the President of the United States;2008. cited 2015 Oct 3. Available from: www.whitehouse.gov/files/documents/ostp/PCAST/pcast_report_v2.pdf.4. Chapple CR, Kaplan SA, Mitcheson D, Blauwet MB, Huang M, Siddiqui E, et al. Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year. Int J Urol. 2014; 21:960–967.5. Kashyap M, Kawamorita N, Tyagi V, Sugino Y, Chancellor M, Yoshimura N, et al. Down-regulation of nerve growth factor expression in the bladder by antisense oligonucleotides as new treatment for overactive bladder. J Urol. 2013; 190:757–764.6. Lee JW, Kim D, Yoo S, Lee H, Lee GH, Nam Y. Emerging neural stimulation technologies for bladder dysfunctions. Int Neurourol J. 2015; 19:3–11.7. Hoggatt J. Personalized medicine: trends in molecular diagnostics: exponential growth expected in the next ten years. Mol Diagn Ther. 2011; 15:53–55.
